Adding a Sodium Glucose Cotransporter 2 Inhibitor to Metformin in a Composite 58-Year-Old With Albuminuric Kidney Disease: The Choice, the Monitoring, and the Teaching
Student Name
Master of Science in Nursing Program, Aspen University
N511: Advanced Pharmacology
Instructor Name
Month Day, Year
The Therapeutic Problem and the Criteria the Answer Has to Meet
The patient described here is a composite created for teaching, and no real person or prescription record is represented; the values are illustrative and are held consistent throughout the paper. The composite is a 58-year-old woman with type 2 diabetes of nine years, treated with metformin 1,000 mg twice daily for the past three years, lisinopril 20 mg daily, and atorvastatin 40 mg daily. Her hemoglobin A1C is 8.3 percent, up from 7.4 percent a year ago. She weighs 96 kg with a body mass index of 34.6, and her blood pressure averages 138/84 mmHg across three seated readings.
Two laboratory values change the question this case asks. Her estimated glomerular filtration rate is 52 mL/min/1.73 m^2, stable across two measurements six months apart, and her urine albumin-to-creatinine ratio is 310 mg/g, against 90 mg/g two years ago. She therefore has albuminuric chronic kidney disease alongside diabetes that is no longer controlled, a pairing that carries a higher risk of progression to kidney failure than either problem produces alone (National Institute of Diabetes and Digestive and Kidney Diseases, 2021). The agent added to metformin here is not being selected only to lower a number; it is being selected to slow the loss of kidney function that the rising albumin ratio is already reporting.
Four constraints narrow the field before any drug is named. She drives a school bus six hours a day, so an agent carrying meaningful hypoglycemia risk creates an occupational hazard rather than an inconvenience. Weight gain would work against both her glycemia and her blood pressure. Her kidney function limits which agents can be given at full dose and which must be reduced or avoided. Her plan sets a 45 dollar monthly copayment tier that some agents fall outside of, and a prescription she cannot fill is not therapy at all.
The criteria that follow from those constraints are stated before any option is examined, which keeps the comparison honest. The agent should lower A1C by roughly one percentage point when added to metformin, carry low intrinsic hypoglycemia risk, be neutral or favorable for weight, have direct trial evidence of slowing kidney disease progression in patients with albuminuria, remain usable at a filtration rate near 50 mL/min/1.73 m^2, and be affordable at her tier. Any candidate meeting five of the six is a serious contender, and the paper defends the one that meets all six.
Defending the Choice Against the Alternatives
The agent defended here is dapagliflozin 10 mg once daily, a sodium glucose cotransporter 2 inhibitor. The drug blocks reabsorption of filtered glucose in the proximal tubule, so glucose and the sodium accompanying it leave in the urine. That single mechanism produces most of what the criteria asked for. Glucose falls without stimulating insulin release, which is why intrinsic hypoglycemia risk is low; the calories lost in the urine produce modest weight reduction; and the sodium delivered to the macula densa restores tubuloglomerular feedback, which lowers pressure inside the glomerulus. That last effect, not the glucose lowering, is what protects the kidney.
The evidence for the kidney claim is direct rather than inferred. In a trial of patients with chronic kidney disease, with and without diabetes, dapagliflozin reduced a composite of sustained decline in filtration rate, end stage kidney disease, and renal or cardiovascular death compared with placebo (Heerspink et al., 2020). An earlier trial of canagliflozin in patients with diabetic nephropathy found the same direction of effect on kidney outcomes (Perkovic et al., 2019). The composite patient here falls inside the enrolled range of the first trial on both entry measures that mattered, filtration rate and albuminuria, which is what makes the evidence applicable to her rather than merely encouraging.
A sulfonylurea is the cheapest option and fails on two criteria at once. It lowers A1C effectively, but it drives insulin release regardless of the glucose level, so hypoglycemia risk is real in a person who drives for a living, and it produces weight gain rather than loss. It offers no kidney or cardiovascular benefit. A dipeptidyl peptidase 4 inhibitor is safer and better tolerated, is weight neutral, and can be dose adjusted for kidney function, but its A1C effect is smaller and it has not demonstrated kidney protection. It satisfies the safety criteria and none of the outcome ones.
The strongest rival is a glucagon-like peptide 1 receptor agonist, which would lower A1C further, reduce weight more, and carry cardiovascular benefit of its own. Current professional guidance treats the two classes as complementary and supports either where kidney and cardiovascular risk drive the decision (American Diabetes Association Professional Practice Committee, 2024; Kidney Disease: Improving Global Outcomes Diabetes Work Group, 2022). It is not the choice for this composite patient for reasons specific to her: an injectable route, gastrointestinal effects during titration, and a copayment above her tier. Naming the better drug she cannot obtain is more honest than pretending the chosen one wins everywhere.
Monitoring, Interactions, and What the Patient Is Taught
Monitoring begins with a value that will look like a failure if it is not anticipated. Filtration rate commonly falls in the first month or two after a sodium glucose cotransporter 2 inhibitor is started, because reducing pressure inside the glomerulus is the point of the drug, and a dip of up to about 30 percent that then stabilizes is expected rather than a reason to stop. For this composite patient the plan is a basic metabolic panel at one month and again at four months, an A1C at three months, a urine albumin-to-creatinine ratio at six months, and weight and blood pressure recorded at every visit.
Each of those has a decision attached to it, which is what separates a monitoring plan from a list of laboratory studies. The A1C at three months answers whether the expected fall of about 0.5 to 0.9 percentage points occurred, and an A1C still above 8.0 percent argues for a third agent rather than for patience. The albumin ratio at six months reports whether the kidney effect is being obtained, and a fall from 310 mg/g is the result being bought. A filtration rate that keeps falling past the early plateau is the finding that would prompt reassessment rather than continuation.
Three interactions matter more than the long list a database returns. She takes no diuretic now, but if one is added for blood pressure it compounds the volume loss this drug already causes and can produce symptomatic hypotension, so the two are reviewed together rather than separately. Insulin or a sulfonylurea added later supplies the hypoglycemia risk this drug does not carry on its own, and those agents are commonly reduced when it is started. A nonsteroidal anti-inflammatory drug taken alongside her lisinopril during a dehydrating illness is the combination most likely to injure her kidney.
Teaching is where this drug succeeds or fails, because most of its harms are prevented by the patient rather than by the clinic. Four points are taught and then confirmed by teach-back. Drink to thirst and do not restrict fluids. Report genital itching or discharge early, since mycotic infection is the commonest reason people stop this class and it is treatable. Hold the drug during any illness with vomiting, poor intake, or fasting, and before a planned procedure, because ketoacidosis can develop at near-normal glucose readings on this class (U.S. Food and Drug Administration, 2015). Expect glucose on a urine dipstick, which is the drug working.
References
American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2024. Diabetes Care, 47(Suppl. 1), S158-S178. https://doi.org/10.2337/dc24-S009
Heerspink, H. J. L., Stefansson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F. F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., Sjostrom, C. D., Toto, R. D., Langkilde, A. M., & Wheeler, D. C. (2020). Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383(15), 1436-1446. https://doi.org/10.1056/NEJMoa2024816
Kidney Disease: Improving Global Outcomes Diabetes Work Group. (2022). KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International, 102(5S), S1-S127. https://kdigo.org/guidelines/diabetes-ckd/
National Institute of Diabetes and Digestive and Kidney Diseases. (2021). Diabetic kidney disease. National Institutes of Health. https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/diabetic-kidney-disease
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., Cannon, C. P., Capuano, G., Chu, P. L., de Zeeuw, D., Greene, T., Levin, A., Pollock, C., Wheeler, D. C., Yavin, Y., ... Mahaffey, K. W. (2019). Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New England Journal of Medicine, 380(24), 2295-2306. https://doi.org/10.1056/NEJMoa1811744
U.S. Food and Drug Administration. (2015). FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections [Drug safety communication]. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-safety-and-availability
How this N 511 Module 5 example is structured
Aspen University does not publish module-by-module deliverable names, so this N511 Module 5 example is written to the genre the module typically wants: a drug therapy paper built on one case rather than a survey of a drug class, and your classroom's instructions and rubric decide the exact form. The structure is built to be argued against. Criteria come first, drawn from the patient's kidney function, occupation, weight, and copayment tier, so the recommendation cannot be reverse engineered from a preferred answer. The defense then measures four options against those criteria and names the rival that would win on other grounds. Monitoring, interactions, and teaching close the paper, because in Advanced Pharmacology a Master of Science in Nursing graduate is judged on the safety system around a drug as much as on the selection itself.
N511 Module 5 questions, answered
What does N511 Module 5 usually ask for?
Aspen does not publish module-by-module deliverable names, so treat any description as typical rather than official. In many sections this module of the advanced pharmacology course asks for a case-based drug therapy paper: one patient, a defended selection, and the monitoring, interactions, and teaching that follow from it. Your classroom's instructions and rubric decide the exact form and citation expectations.
Do I need to be a prescriber to write a drug therapy paper?
No. Many master's students in nursing are working nurses moving into education, leadership, or informatics, and this paper is an analysis rather than an order. The sample defends a selection against stated criteria, builds the monitoring that makes it safe, and documents teaching, all of which a graduate nurse is expected to reason through and explain to others.
How many alternatives should I compare, and how deeply?
Three named rivals is usually enough if each is beaten on criteria you stated first. The sample rejects a sulfonylurea and a dipeptidyl peptidase 4 inhibitor in a few sentences each, then spends a full paragraph on the option that would have won on other grounds. Depth belongs with the strongest rival, not spread evenly across every drug in the class.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official Aspen University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.